ALSTON & BIRD LLP for TRAVERE THERAPEUTICS
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Intellectual property issues and commercial litigation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Health Issues HCR
Rare disease patient care and screening; S. 3056, Creating and Restoring Equal Access to Equivalent Samples Act of 2016 or the CREATES Act of 2016; H.R. 2051, FAST Generics Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| Y. BRIAN LEE New | Legislative Intern, Rep. Doug Lamborn. |
| MARK RAYDER | — |
| REGINA MARIA SHERICK New | Staff Assistant, Senate Finance Committee. |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Medicare/Medicaid MMM
Issues related to H.R. 1628, American Health Care Act of 2017; Better Care Reconciliation Act (S.__).
| Lobbyist | Covered position, as disclosed |
|---|---|
| Y. BRIAN LEE New | Legislative Intern, Rep. Doug Lamborn. |
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Pharmacy PHA
Orphan Drug Act, Drug Quality and Security Act, drug pricing, Prescription Drug User Fee Act reauthorization, H.R. 2430/S. 934, FDA Reauthorization Act of 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| Y. BRIAN LEE New | Legislative Intern, Rep. Doug Lamborn. |
| MARK RAYDER | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Medical/Disease Research/Clinical Labs MED
Medical research, NIH funding, FDA personnel issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| Y. BRIAN LEE New | Legislative Intern, Rep. Doug Lamborn. |
| MARK RAYDER | — |
| REGINA MARIA SHERICK New | Staff Assistant, Senate Finance Committee. |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.